Scarica l'app Stockscreener
6.78
0.22%
-0.00
Dopo l'orario di chiusura:
6.77
-0.01
-0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHC Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$6.78
Aprire:
$6.78
Volume 24 ore:
630.15K
Relative Volume:
0.32
Capitalizzazione di mercato:
$2.51B
Reddito:
$9.47B
Utile/perdita netta:
$-178.00M
Rapporto P/E:
-14.13
EPS:
-0.48
Flusso di cassa netto:
$1.01B
1 W Prestazione:
+7.21%
1M Prestazione:
+6.03%
6M Prestazione:
-12.37%
1 anno Prestazione:
+15.05%
Intervallo 1D:
$6.63
$6.84
Intervallo di 1 settimana:
$6.29
$6.895
Portata 52W:
$4.25
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Nome
Bausch Health Companies Inc
Settore
Telefono
514-744-6792
Indirizzo
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Confronta BHC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
6.78 | 2.46B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
152.12 | 68.32B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.48 | 46.55B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.875 | 43.80B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.55 | 19.01B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
304.50 | 13.79B | 2.99B | 1.21B | 1.13B | 25.06 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-06-16 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Downgrade | Truist | Buy → Hold |
| 2022-07-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Ripresa | JP Morgan | Overweight |
| 2021-03-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-24 | Iniziato | Citigroup | Buy |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Iniziato | Goldman | Neutral |
| 2019-10-25 | Iniziato | Cowen | Outperform |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-08-15 | Aggiornamento | TD Securities | Hold → Buy |
| 2019-07-19 | Iniziato | Wolfe Research | Outperform |
| 2019-06-11 | Ripresa | Barclays | Overweight |
| 2019-05-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-01-02 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Aggiornamento | Piper Jaffray | Underweight → Neutral |
Mostra tutto
Bausch Health Companies Inc Borsa (BHC) Ultime notizie
Bausch Health Companies Inc. Stock Analysis and ForecastTremendous financial leverage - PrintWeekIndia
Is Bausch Health Companies Inc. stock a good hedge against inflationExplosive wealth accumulation - jammulinksnews.com
Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com South Africa
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors - The Joplin Globe
Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan
Is Bausch Health Companies Inc. a good long term investmentFast-track wealth growth - Autocar Professional
Hyperammonemia Market Trends 2025: Growth Drivers & Forecast | - openPR.com
What drives Bausch Health Companies Inc. stock pricePhenomenal wealth increase - jammulinksnews.com
IP Atty's FCA Suit Against Valeant Over Apriso Tossed Again - Law360
SANDRIDGE ENERGY, INC. ANNOUNCES APPOINTMENT OF BRETT ICAHN TO THE BOARD OF DIRECTORS - The Malaysian Reserve
What analysts say about Bausch Health Companies Inc. stockTremendous return on equity - jammulinksnews.com
Brett Icahn Takes Board Seat at SandRidge Energy: Major Strategic Move for Oil Producer - Stock Titan
Best Stock to Buy Right Now: Bausch Health vs Canopy Growth? - MSN
Bausch Health Faces Patent Drama And Policy Questions This Quarter - Finimize
Bausch Health's Xifaxan Patent Clarity, Policy Commentary in Focus for Q2, RBC Says - MarketScreener
In the Wake of Bausch Health Companies Inc.'s (NYSE:BHC) Latest US$196m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛
In the wake of Bausch Health Companies Inc.'s (NYSE:BHC) latest US$196m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
Amblyopia Market Growth Expected to See Next Level with Novartis - openPR.com
Bausch Health Companies (BHC) Canada Announces Expanded Availability of CABTREO Gel - Yahoo Finance
Icahn Enterprises shares rise 5.72% intraday after Bausch Health appoints new Chief Accounting Officer. - AInvest
Bausch Health's Strategic Leadership Shift: Steven Lee's Expertise Could Propel Valuation Growth Amid Transformation - AInvest
First-Ever Triple-Combination Acne Treatment CABTREO Expands Access Across Canadian Health Programs - Stock Titan
Bausch Health Names Steven Lee Chief Accounting Officer - MarketScreener
Bausch Health Appoints New Chief Accounting Officer - MarketScreener
Bausch Health Strengthens Finance Team: M&A Expert Steven Lee Takes Chief Accounting Officer Role - Stock Titan
Groundbreaking Triple-Combination Acne Treatment Expands Access Across Canadian Healthcare System - Stock Titan
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence - New Castle News
First FDA-Approved Drug Xifaxan Unveils Powerful Patient Stories in New Hepatic Encephalopathy Campaign - Stock Titan
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bausch Health Companies Reaches Analyst Target Price - Nasdaq
August 22nd Options Now Available For Bausch Health Companies (BHC) - Nasdaq
Stocks In Play: Bausch Health Companies - Barchart.com
Bausch Health to Announce Second Quarter 2025 Results on July 30 - Corsicana Daily Sun
Bausch Health Companies Inc Azioni (BHC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.79%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):